Novel mutations of PKD genes in the Czech population with autosomal dominant polycystic kidney disease by Lena Obeidova et al.
Obeidova et al. BMC Medical Genetics 2014, 15:41
http://www.biomedcentral.com/1471-2350/15/41RESEARCH ARTICLE Open AccessNovel mutations of PKD genes in the Czech
population with autosomal dominant polycystic
kidney disease
Lena Obeidova1, Veronika Elisakova1*, Jitka Stekrova1, Jana Reiterova2, Miroslav Merta1, Vladimir Tesar2,
Frantisek Losan3 and Milada Kohoutova1Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal
disorder caused by mutation in either one of two genes, PKD1 and PKD2. High structural and sequence complexity
of PKD genes makes the mutational diagnostics of ADPKD challenging. The present study is the first detailed
analysis of both PKD genes in a cohort of Czech patients with ADPKD using High Resolution Melting analysis
(HRM) and Multiplex Ligation-dependent Probe Amplification (MLPA).
Methods: The mutational analysis of PKD genes was performed in a set of 56 unrelated patients. For mutational
screening of the PKD1 gene, the long-range PCR (LR-PCR) strategy followed by nested PCR was used. Resulting PCR
fragments were analyzed by HRM; the positive cases were reanalyzed and confirmed by direct sequencing. Negative
samples were further examined for sequence changes in the PKD2 gene by the method of HRM and for large
rearrangements of both PKD1 and PKD2 genes by MLPA.
Results: Screening of the PKD1 gene revealed 36 different likely pathogenic germline sequence changes in 37
unrelated families/individuals. Twenty-five of these sequence changes were described for the first time. Moreover,
a novel large deletion was found within the PKD1 gene in one patient. Via the mutational analysis of the
PKD2 gene, two additional likely pathogenic mutations were detected.
Conclusions: Probable pathogenic mutation was detected in 71% of screened patients. Determination of PKD
mutations and their type and localization within corresponding genes could help to assess clinical prognosis of
ADPKD patients and has major benefit for prenatal and/or presymptomatic or preimplantational diagnostics in
affected families as well.
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ADPKD is a hereditary renal disorder with the incidence
of 1:400 to 1:1000 live births, characterized by focal
development and progressive enlargement of cysts in kid-
neys leading to the decline of renal function. End-stage
renal disease (ESRD) occurs during the late phase of the
illness and the majority of patients have to start dialysis
and/or undergo kidney transplantation. The disease is fre-
quently accompanied by many extra-renal symptoms,* Correspondence: velisakova@post.cz
1Institute of Biology and Medical Genetics of the First Faculty of Medicine
and General University Hospital, Albertov 4, 128 00 Prague, Czech Republic
Full list of author information is available at the end of the article
© 2014 Obeidova et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsuch as hypertension, formation of cysts in liver or
pancreas, abnormalities of cardiovascular system or
development of brain-aneurysms [1].
ADPKD is genetically determined by two genes, PKD1
(16p13.3) [2] and PKD2 (4q21-22) [3]. In clinical identified
populations, mutations of the PKD1 gene account for ap-
proximately 85% of all ADPKD cases and are responsible
for more serious form of the disease (the average age at
the onset of ESRD is 58) [4]. Fifteen percent of ADPKD
patients with milder clinical presentation (the average age
at the onset of ESRD is 79) carry mutation in the PKD2
gene [5,6]. The hypothetical existence of the third PKD
locus has not been supported by new reports [7,8].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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brane protein called polycystin-1 (4303 amino acids).
The PKD2 gene product (15 exons) is an integral mem-
brane protein polycystin-2 (968 amino acids) that acts as
a transient receptor potential (TRP) ion channel invol-
ved in the regulation of intracellular Ca2+ concentration.
Both proteins interact with each other in kidney primary
cilia forming complex that hypothetically functions as a
flow-dependent mechanosensor with a crucial role in
the adhesion, proliferation and differentiation of tubular
epithelial cells [9,10].
Both genes are highly polymorphic and sequence
changes are spread over their whole length [11]. The
majority of mutations are unique to a single family, re-
current mutations account only for 30% of the total [12].
Currently, 978 sequence variants of the PKD1 gene and
193 sequence variants of the PKD2 gene have been pub-
lished in the Human Gene Mutation Database (HGMD)
(http://www.hgmd.cf.ac.uk). The specialized Autosomal
Dominant Polycystic Kidney Disease Mutation Database
(PKDB) presents even 1,923 different sequence variants
of PKD1 and 241 sequence variants of the PKD2 gene
(http://pkdb.mayo.edu; [13]).
The high variability of sequence changes is not the
only fact that makes the analysis of PKD genes difficult.
First 33 exons of the PKD1 gene are duplicated six times
with 97% sequential identity. These pseudo genes are
located in the close surroundings of the original gene
and significantly complicate the mutational screening of
the PKD1 gene [14].
The clinical course of ADPKD is highly variable not
only among families with different mutations but within
families with a defined mutation as well. The large
phenotypic variability of ADPKD within affected families
highlights a role for the genetic background in disease
presentation. Hypomorphic or incompletely penetrant
PKD1 or PKD2 alleles have been described, causing mild
cystic disease [15,16]. Coinheritance of hypomorphic
allele in combination with an inactivating PKD allele can
be associated with early-onset disease. About 2% of
ADPKD patients show such an early and severe pheno-
type (renal enlargement in utero or in infancy) that can
be clinically indistinguishable from autosomal recessive
polycystic kidney disease (ARPKD). These severe cases
have been explained by the presence of the expected
familial germ-line mutation and, in addition, other sup-
plementary mutations in PKD genes (including PKD1,
PKD2, PKHD1 and also HNF-1β gene), which act as
modifying genes and likely aggravate the final phenotype
[17]. Moreover, mosaicism can also modulate the course
of ADPKD in some families [16,18,19].
Diagnosis of ADPKD is usually based on an age-
specific phenotype of affected kidneys (number and size
of renal cysts on the ultrasound, computed tomographyor magnetic resonance imaging), accompanying factors
(for example hypertension) and positive family history
[19-21]. Molecular diagnostics (traditional linkage analysis
or direct mutational screening) is a useful tool to deter-
mine and confirm the definite diagnosis, especially for
evaluation of potential living related kidney donors, for
individuals with negative family history and for patients
with early onset of ADPKD [22]. Molecular analysis of
PKD genes is quite complicated and time-consuming,
therefore new methods are being developed to simplify
the whole process [23-25].
In the present study, the mutational analysis of both
PKD genes in a cohort of 56 Czech patients with ADPKD
was performed using HRM and MLPA techniques.
Methods
Patients
The mutational screening of PKD genes was performed
in a set of 56 unrelated Czech patients with ADPKD
diagnosed by renal ultrasound in accordance with previ-
ously described criteria [26]. The study was approved by
the Ethics Committee of General University Hospital in
Prague on May 23, 2006. All patients provided written
informed consent. According to the linkage analysis, the
disease was linked to the PKD1 gene in 20 individuals.
In 26 patients a relation of the disease to the PKD1 gene
was not proved and 10 patients had an isolated occur-
rence of the disease within a family.
Linkage analysis
Linkage analysis was carried out using a panel of CA-
repeat flanking markers. The combination and number
of markers used for analysis were selected to achieve at
least two informative markers, one on the 5′end and the
second on the 3′end of PKD gene to rule out possible
recombination. The markers used for PKD1 analysis
were: D16S521, D16S3024, KG8, CW4, CW3, CW2, and
for PKD2 analysis: D4S231, D4S1534, JSTG3, JV108,
AICA1, D4S1563 and D4S414.
Mutational screening
The genomic DNA was isolated from the peripheral
blood lymphocytes using QIAGEN spin columns on a
QIAcube (QIAGEN GmbH).
At first, the screening of the PKD1 gene was carried
out in the selected set of 56 patients. For mutational
analysis of the PKD1 gene, the technique of a long-range
PCR (LR-PCR) followed by nested PCR was used [27].
Nested PCR amplicons were produced and analyzed by
the method of High Resolution Melting (HRM); positive
clones were reanalyzed and confirmed by sequencing in
both directions. The protocol of the whole strategy (includ-
ing primers and PCR reaction conditions) was previously
described in detail by Reiterova et al. [16].
Obeidova et al. BMC Medical Genetics 2014, 15:41 Page 3 of 12
http://www.biomedcentral.com/1471-2350/15/41The DNA of patients where no definite pathogenic
mutation was found within the PKD1 gene (29 samples)
were subsequently analyzed via mutational screening of
the PKD2 gene by HRM and via MLPA for large rear-
rangements of both PKD1 and PKD2 genes. This subset
of 29 individuals included patients without any sequence
changes found by mutational analysis of the PKD1 gene
as well as patients with unpublished putative missense
mutations, putative splice-site mutations and in-frame
deletions/insertions detected in the PKD1 gene.
The coding region and intron-exon boundaries of the
PKD2 gene were screened via 17 PCR fragments. The
sequences of PCR primers (some primers were designed
on the base of Tan et al.) and the conditions of PCR
reactions are available upon request [28]. PCR fragments
were produced and analyzed by HRM using the LightCy-
cler® 480 (Roche Applied Science). The reaction mixture
(total volume of 10 μl) contained 1 μl of diluted template
DNA, 1 × LightCycler® 480 High Resolution Melting
Master Mix (Roche Applied Science) and 5 pmol of
primers. The LightCycler® 480 Gene Scanning Software
(Roche Applied Science) analyses the melting profile of
samples to identify changes in the shape of melting
curves, which indicate both homozygous and heterozy-
gous allelic variants in a sample (Figure 1) [29]. All PCR
fragments showing aberrant melting curves by HRM
were sequenced. The sequencing reaction was performed
according to the manufacturer’s instructions using the
BigDye® Terminator v1.1 Cycle Sequencing Kits (Applied
Biosystems) and ran on an ABI PRISM® 310 Genetic
Analyser (Applied Biosystems).
MLPA analysis (MRC-Holland) was carried out with
SALSA MLPA KIT P351-B1/P352-B1 PKD1-PKD2,
which together covers 37 from 46 exons of the PKD1
gene, its upstream regulatory sequences, entire PKD2
gene and three exons of the TSC2 gene adjacent to the
PKD1 gene [30]. The MLPA reaction was performed
with 50–100 ng of genomic DNA according to the man-
ufacturer’s instructions. The result of MLPA was carried
out by fragmentation analysis with the use of ABI PRISM®
310 Genetic Analyser (Applied Biosystems). To obtain the
final results, the generated raw data were normalized
according to the manufacturer’s instructions. At first
intra-sample normalization was performed by dividing the
peak area of each probe’s amplification product by the
total area of only the reference probes in the probemix.
Subsequently, the normalization between individual sam-
ples was done by dividing the intra-normalized probe ratio
of each sample by the average intra-normalized probe
ratio of reference samples (negative controls). In-house
developed method was used for the entry of all these
calculations.
To prove the segregation of the potential mutation in
PKD genes with the disease in the family, the DNAs ofall available members of the respective family (including
healthy individuals) were tested as well.Data analysis and sequence changes classification
All sequenced samples were compared to the following
NCBI reference sequences: [GeneBank: NM_001009944.2]
for the PKD1 gene and [GeneBank: NM_000297.3] for the
PKD2 gene. The sequence changes found within this study
were checked with the list of PKD sequence variants cur-
rently published in the Human Gene Mutation Database
(HGMD) (http://www.hgmd.cf.ac.uk) and the Autosomal
Dominant Polycystic Kidney Disease Mutation Database
(PKDB) (http://pkdb.mayo.edu). In case of novel muta-
tions, their pathogenic potential was assessed. Nonsense
or frameshift variants leading to a premature STOP codon
were considered as definitely pathogenic.
The pathogenic potential of missense variants was
evaluated computationally by examining interspecies se-
quence variations using PolyPhen2 (http://genetics.bwh.
harvard.edu/pph2/; [4,31,32]) and Sorting Intolerant from
Tolerant (SIFT) (http://sift.bii.a-star.edu.sg/; [4,32,33]) soft-
ware. The sequence variant was considered as likely patho-
genic, if both scores assessed its pathogenity. When only
one test predicted the pathogenic potential, the variation
was reported as indeterminate. The pathogenic relevance
of putative splice site mutations was evaluated in the same
way using NetGene2 (http://www.cbs.dtu.dk/services/Net
Gene2/; [34]) and Human Splicing Finder (HSF) (http://
www.umd.be/HSF/; [35]) software. Further criteria for clas-
sification of missense or splice site variant as likely patho-
genic mutation were its segregation within the affected
family and absence of additional, more probable mutation
in a concrete patient (family).
Possible influence of sex and type of mutations on the
age of renal failure was evaluated. For this purpose,
Shapiro-Wilk normality test for each group was performed
and subsequently, according to results of normality test,
unpaired two-sample t-test was used to compare the
groups. All computations were carried out using in-house
developed scripts in R language.Results
We performed mutational analysis in PKD genes in a set
of 56 unrelated Czech patients with ADPKD diagnosed
by renal ultrasound. Twenty selected individuals came
from families where ADPKD was linked unequivocally
to the PKD1 gene according to the linkage analysis.
Other 26 cases were the families with more serious
manifestation of the disease (ESRD before 60 years of
age). In this group of patients, a direct relation of the
disease to the PKD1 gene has not been proven by the
method of linkage analysis. At last, 10 unrelated individ-






Figure 1 The example of HRM analysis in patients 385 and 419 (exon 39). 1 Detection of mutations by HRM. The green curve in the
diagram corresponds to the PCR fragment carrying the nonsense mutation c.11172G > A (p.Trp3724X) in patient 385. The red curve refers to the
PCR fragment carrying the likely pathogenic substitution c.11248C > G (p.Arg3750Gly) in patient 419. The rest of fragments with blue curves are
wild type samples (patients without sequence changes). 2, 3 Confirmation of mutations by direct sequencing in patient 385 (number 2) and
patient 419 (number 3). Both sequences are in reverse direction. The letter A corresponds to the mutated sequence; B is the wild type.
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mutation).
Mutational screening of the PKD1 gene revealed 38 (36
different) likely pathogenic sequence changes in 37 fromthe total set of 56 patients (Table 1). In one individual,
two different likely pathogenic mutations were found.
In total, eleven frameshift mutations (29%), nine non-
sense mutations (24%), eleven missense mutations (29%),
Table 1 Likely pathogenic sequence changes of the PKD1 gene identified by HRM and direct sequencing in a set of
patients from the Czech population
Family Exon/intron Nucleotide change Amino acid change/predicted effect
Predicted location
within PKD1 domains Reference
394 ISOL. 4 c.450_459del10 p.Glu151ArgfsX135 LRRNT Novel
338 PKD1 7 c.1564 T > C p.Cys522Arg C-type lectin domain Novel
39 INDET. 15 c.3312_3313dupC p.Val1105ArgfsX4 PKD repeats [16]
429 PKD1 15 c.4551_4581del31 p.Tyr1517X PKD repeats Novel
236 PKD1 15 c.5650G > T p.Glu1884X PKD repeats Novel
478 INDET. 15 c.5824_5825dupC p.Arg1942ProfsX47 PKD repeats [36]
301 PKD1
15 c.5995G > A p.Gly1999Ser PKD repeats [12]
496 ISOL.
315 PKD1 15 c.6130A > G p.Asn2044Asp PKD repeats Novel
249 INDET. 15 c.6586C > T p.Gln2196X REJ domain Novel
427 ISOL. 15 c.6895delG p.Ala2299ProfsX14 REJ domain Novel
237 PKD1 16 c.6960_6961insG p.Ser2321GlufsX98 REJ domain Novel
253 PKD1 16 c.7000_7001dupGCTGGCG p.Val2334GlyfsX87 REJ domain [37]
246 PKD1 17 c.7144_7156del13insTAC p.Ser2382TyrfsX234 REJ domain Novel
112 INDET. 18 c.7484G > A p.Cys2495Tyr REJ domain Novel
403 PKD1 20 c.7758_7761del4 p.Trp2587CysfsX31 REJ domain Novel
357 INDET. 20 c.7856 T > G p.Leu2619Arg REJ domain Novel
438 ISOL. 23 c.8309A > T p.Asn2770Ile REJ domain [36]
336 INDET.
23 c.8311G > A p.Glu2771Lys REJ domain [37]
389 PKD1
275 ISOL. 23
c.8428G > T p.Glu2810X REJ domain [38]
c.8614delA p.Ile2872SerfsX3 [39]
482 INDET. IVS23 c.8792-2A > T Probable splice defect N/A Novel
479 INDET. 27 c.9416_9417dupACGTGGG p.Ile3140ArgfsX40 PLAT domain Novel
430 PKD1 28 c.9584G > A p.Trp3195X PLAT domain Novel
391 PKD1 29 c.9904G > C9906_9907delTG p.Val3302LeufsX86 TM domain Novel
395 ISOL. 33 c.10321C > T p.Gln3441X Not defined Novel
413 INDET. IVS36 c.10821 + 4_10821 + 6delAGG Probable splice defect N/A Novel
330 INDET. 37 c.10951G > A p.Gly3651Ser Not defined [40]
297 PKD1 37 c.10980_10982delAGC p.Glu3660_Ala3661delinsAsp Not defined Novel
385 INDET. 39 c.11172G > A p.Trp3724X PKD channel domain Novel
419 INDET. 39 c.11248C > G p.Arg3750Gly PKD channel domain Novel
379 INDET. 41 c.11482_11484delGAG p.Glu3828del PKD channel domain [40]
420 PKD1 43 c.11884 C > T p.Gln3962X PKD channel domain Novel
161 INDET. 43 c.11993_11994dup9 p.Leu3998_Leu3999insPheLeuLeu PKD channel domain Novel
425 INDET. IVS43-44 c.12004-15_12015del27 Probable splice defect N/A Novel
215 PKD1 44 c.12061 C > T p.Arg4021X PKD channel domain [41]
454 INDET. 45 c.12439_12441delAAG p.Lys4147del Not defined Novel
cDNA numbering is based on the reference database: Autosomal Dominant Polycystic Kidney Disease Mutation Database (PKDB) (http://pkdb.mayo.edu). Novel
probable mutations are in boldface type. ISOL. patients with isolated occurrence of ADPKD in a family; PKD1 patients with proved linkage of ADPKD to the PKD1
gene; INDET. indeterminate patients (the linkage of ADPKD to PKD1 gene has not been proved); IVS – the intronic sequence; Novel mutation was not described in
the Autosomal Dominant Polycystic Kidney Disease Mutation Database (PKDB) (http://pkdb.mayo.edu) and/or in the Human Gene Mutation Database (HGMD)
(http://www.hgmd.cf.ac.uk). The potential location of mutations has been established on the basis of theoretical model of polycystin-1 by UniProtKB/Swiss-Prot
database [P98161]. LRRNT – leucine rich repeat N-terminal domain; REJ – receptor for Egg Jelly; PLAT – Polycystin-1, Lipoxygenase, Alpha-Toxin domain;
TM – transmembrane domain. As not defined are called sequences within PKD1 protein with unknown domain structure.
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putative splice-site mutations (8%) were detected in our
set of patients. Via MLPA, one additional new large dele-
tion was found within the PKD1 gene.
Fifty-seven percent (21) of likely pathogenic mutations
found matched the definitions of being definitely patho-
genic. Twenty-six of the mutations found in this study
were novel. Moreover, three additional indeterminate
sequence changes (two missense and one splice-site)
were described (Table 2).
A great deal of sequence variants of the PKD1 gene
detected in our study were changes which do not alter the
amino acid composition or have been already published as
polymorphisms (or sequence changes with neutral effect
on the function of polycystin 1). Complementary muta-
tional analysis of the PKD2 gene revealed two already
described likely pathogenic mutations and one indeter-
minate splice-site variant. All three sequence changes
were found within patients without proven linkage of
ADPKD to the PKD1 gene (Table 2 and 3). Screening of
the PKD2 gene thus increased the final detection level
of likely pathogenic mutations in this study to 71%
(40 patients with a putative mutation from the set of 56
individuals in total).
Regarding the distribution of revealed mutations
among the patients with distinctive phenotype and a
family history, 16 likely pathogenic mutations (42%)
were found in a cohort with more serious manifestation
of ADPKD (ESRD reached before the age of 60 years).
Fifteen putative mutations (approximately 40%) were
detected among families with clear linkage to the PKD1
gene. The rest (18% of likely pathogenic mutations)
referred to the set of patients without positive family
history (isolated occurrence in a family).
From all 56 patients and their analyzed affected rela-
tives, 20 males and 17 females have already reached
ESRD (Table 4). Computation of dependency of sex and
type of mutation (missense and small in-frame indels vs.
truncating mutations) on the age of ESRD was performed
in a group of 37 individuals. According to the Shapiro-Wilk
test of normality, all tested groups had normal distributionTable 2 Indeterminate sequence changes of PKD genes ident
from the Czech population
Family Gene/exon/intron Nucleotide change Amino acid change/p
308 INDET. PKD1/15 c.3602C > T p.Ala1201Val
412 INDET. PKD1/29 c.9718G > A p.Ala3240Thr
409 INDET. PKD1/IVS42 c.11712 + 8C > A Probable splice defect
466 INDET. PKD2/IVS 9 c.2019 + 9A > C Probable splice defect
cDNA numbering is based on the reference database: Autosomal Dominant Polycys
indeterminate patients (the linkage of ADPKD to PKD1 gene has not been proved);
Autosomal Dominant Polycystic Kidney Disease Mutation Database (PKDB) (http://p
(http://www.hgmd.cf.ac.uk). The potential location of mutations has been establishe
database (PKD1: P98161, PKD2:Q13563). As not defined are called sequences within(p > 0.1). Two-sample t-test did not reject null hypothesis
in either sex (t = −0.9, p = 0.4), or type of mutation (t = 0.8,
p = 0.4) dependency on age of renal failure.Nonsense and frameshift mutations
One patient (275) from our study was found to have two
truncating pathogenic mutations (one nonsense mutation
and one frameshift mutation), both already published and
both located within the exon 23 probably in cis regarding
his mild phenotype of ADPKD without progression. Simi-
lar cases have been already described in the literature, but
their existence is rare [11]. The patients 394, 395 and 427
are the representatives of the group with isolated occur-
rence of ADPKD within their families.Missense mutations
Via our mutational analysis of both PKD genes, 9 likely
pathogenic missense mutations have been identified; all
within the PKD1 gene. Five mutations have been deter-
mined as novel and two already published substitutions
(p.Gly1999Ser and p.Glu2771Lys) were recurrent (both
present in two different individuals). Eight substitutions
segregated with the disease in affected families (Table 5)
and were confirmed as pathogenic by both predictor pro-
grams (PolyPhen2 and SIFT), one substitution occurred
de novo.Splice-site mutations
The probable splice-site mutations c.8792-2A > T (patient
482) and c.12004-15_12015del27 (patient 425) cover the
consensus sequence of conserved splice-site and both
predictor programs suggested their pathogenity. Although
the probable splice-site mutation c.10821 + 4_10821 +
6del AGG (patient 413) is also situated within the con-
served splice-site, its pathogenic impact is milder. Accord-
ing to NetGene2 and HSF, this mutation does not abolish
the splice-site completely but decreases its efficiency
significantly. Therefore this mutation was classified as
pathogenic as well.ified by HRM and direct sequencing in a set of patients





tic Kidney Disease Mutation Database (PKDB) (http://pkdb.mayo.edu). INDET.
IVS the intronic sequence; Current paper mutation was not described in the
kdb.mayo.edu) and/or in the Human Gene Mutation Database (HGMD)
d on the basis of theoretical models of polycystins by UniProtKB/Swiss-Prot
PKD proteins with unknown domain structure.
Table 3 Likely pathogenic sequence changes of the PKD2 gene identified by HRM and direct sequencing in a set of
patients from the Czech population
Family Exon/intron Nucleotide change Amino acid change Predicted location within PKD2 domains Reference
421 INDET. 6 c.1345_1346insGCAACAG Gly450AsnfsX22 Polycystin cation channel domain [42]
467 INDET. IVS 11 c.2240 + 1G > T Splice N/A [43]
cDNA numbering is based on the reference database: Autosomal Dominant Polycystic Kidney Disease Mutation Database (PKDB) (http://pkdb.mayo.edu). INDET.
indeterminate patients (the linkage of ADPKD to PKD1 gene has not been proved); IVS the intronic sequence. The potential location of mutations has been
established on the basis of theoretical model of polycystin-2 by UniProtKB/Swiss-Prot database [Q13563].
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Within our set of 56 Czech individuals (families), four
small in-frame deletions/insertions were detected; three
of them were described as novel. The common molecu-
lar mechanisms of origin of such genomic events are
non-homologous end joining (NHEJ) or microhomology-
mediated replication-dependent recombination (MMRDR)
[44]. All three novel small in-frame deletions/insertions
characterized in the present study show high evolutionary
conservation of involved amino acid residues; all three are
the only probably pathogenic mutations identified in
the patient and segregate with the disease in affected
families (Table 5). Their pathogenic potential is there-
fore highly probable.Table 4 Ages of end stage renal disease in families with likely
Family Nucleotide change Amino acid change/p
429 c.4551_4581del31 p.Tyr1517X
236 c.5650G > T p.Glu1884X
478 c.5824_5825dupC p.Arg1942ProfsX47




357 c.7856 T > G p.Leu2619Arg
482 c.8792-2A > T Probable splice defect
479 c.9416_9417dupACGTGGG p.Ile3140ArgfsX40
430 c.9584G > A p.Trp3195X
391 c.9904G > C9906_9907delTG p.Val3302LeufsX86
413 c.10821 + 4_10821 + 6delAGG Probable splice defect
330 c.10951G > A p.Gly3651Ser
297 c.10980_10982delAGC p.Glu3660_Ala3661deli
385 c.11172G > A p.Trp3724X
419 c.11248C > G p.Arg3750Gly
420 c.11884 C > T p.Gln3962X
425 c.12004-15_12015del27 Probable splice defect
215 c.12061 C > T p.Arg4021X
454 c.12439_12441delAAG p.Lys4147delLarge rearrangements
By the method of MLPA, one novel large deletion of the
PKD1 gene was revealed in patient 105 with proven linkage
of ADPKD to the PKD1 gene. The deletion was spread from
the exon 3 to the first half of exon 15. The exact beginning
of the deletion is arguable, because there is no probe for
exon 2 in the MLPA kit used within our study. The dele-
tion was identified in all available affected members of the
family but was not characterized at the nucleotide level
due to the sequence complexity of the PKD1 locus.
Indeterminate sequence changes
Four sequence changes found within our set of patients
were categorized as indeterminate (Table 2). The possiblepathogenic mutation found in the PKD1 gene
redicted effect Ages of end stage renal disease in the familyin years, M-male, F-female




M 48, F 45
M 61, M 60, M 36
F 60
M 41, F 57
M 43




F73, F71, M 73
nsAsp M 41, F 44, F 35
F 49
F 44
F 45, F 46
F 65, F 51
F 58, M 50, M 50
M 67
Table 5 Segregation of likely pathogenic missense and small in-frame indel mutations of PKD1 with polycystic kidney
disease in affected families
Amino acid change Nucleotide change Family Number of affected/healthy family members
p.Cys522Arg c.1564 T > C 338 5/2
p.Gly1999Ser c.5995G > A 301 3/2
p.Asn2044Asp c.6130A > G 315 6/4
p.Cys2495Tyr c.7484G > A 112 3/3
p.Leu2619Arg c.7856 T > G 357 2/3
p.Glu2771Lys c.8311G > A
336 2/1
389 6/5
p.Gly3651Ser c.10951G > A 330 2/3
p.Arg3750Gly c.11248C > G 419 2/2
p.Glu3660_Ala3661delinsAsp c.10980_10982delAGC 297 2/4
p.Leu3998_Leu3999insPheLeuLeu c.11993_11994dup9 161 3/3
p.Lys4147del c.12439_12441delAAG 454 3/2
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c.2019 + 9A >C segregate with the disease in affected
families and are the only possible mutations found in pa-
tients 409 and 466, respectively. However, their location is
out of the conventional range of the consensus splice-site
sequence and both predictor programs (NetGene2 and
HSF) evaluated them as non-pathogenic. Despite its segre-
gation within affected family, also the substitution PKD1/
p.Ala1201Val (patient 308) was determined as benign by
both software programs used (PolyPhen2 and SIFT). Al-
though the substitution PKD1/p.Ala3240Thr (patient 412)
was predicted as possibly damaging by PolyPhen2, SIFT
defined it as benign as well.
Discussion
The highest portion of mutations found within our study
(54%) was predicted to truncate the protein. These trun-
cating changes include frameshift mutations, nonsense
mutations and one large deletion. Our findings seem to
be in concordance with the recent publication by
Cornec-Le Gall et al., where approximately two thirds of
PKD1 mutation-positive pedigrees carried truncating
mutations [6]. In addition, the most frequent definitely
pathogenic mutation type of the PKD1 gene in our study
is a frameshift mutation (29%), which is consistent with
detailed current reports [6,12,36].
Characterization of mutations
In the present study, only 5.3% of mutations were recur-
rent (2 different already published mutations, both found
in two different unrelated families). Both these mutations
occur within CpG dinucleotides (G > A transitions), which
are mutational hotspots typical for recurrent sequence
changes [45]. The substitution p.Glu2771Lys is even pub-
lished for the sixth time (always from a different location).This fact strongly supports its recurrent origin instead of
the existence of a common ancestor.
Such a low percentage of recurrent mutations is in
contrast with studies by other groups. Up to 30% of
recurrent mutations were mentioned regarding PKD
genes in the study by Rossetti et al. [12]. Also, the latest
comprehensive mutational analysis of PKD genes in 700
unrelated patients revealed 20.8% of recurrent mutations
[36]. The difference can be caused by a smaller number
of patients analyzed within our study (56) compared to
extensive studies by Rossetti et al. (202) and Audrézet
et al. (700).
According to the recent data from literature, ADPKD
without family history is present in about 10% of adult
patients [46]. The clinical characteristics of patients with
and without family history are very similar but only
about a half of patients without positive family history
show extrarenal abnormalities. In our case, 18% of found
likely pathogenic mutations fall into the group of pa-
tients with isolated occurrence of ADPKD (the so called
de novo mutations).
Large DNA rearrangements account for a maximum
of 4% of all PKD1 mutations and even fewer of all PKD2
mutations [18]. Finding of only one large deletion of the
PKD1 gene within our set of patients (approximately
2.5%) is thus in accordance with the data from literature.
Location of mutations
Sequence changes of all types were spread throughout
the PKD1 gene (Table 1). The only evidence of a cluster
of mutations (especially truncations) was at the end of
exon 15. This region corresponds to the junction of the
PKD repeats and the REJ domain of the resulted protein.
The reference about this sort of clustering has been
already mentioned in literature by Rossetti et al. [12].
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PKD2 gene can be done as only one exonic mutation
was found. Both PKD genes are characterized by a high
level of allelic heterogeneity (a great number of polymor-
phisms), relatively high GC content and no mutation
hotspots. The mutations are usually unique, highly vari-
able and spread throughout the entire gene which fully
corresponds with our observations [13]. However, the
latest comprehensive study of PKD genes suggests the
existence of theoretical hotspots for the three major
types of mutations within the PKD1 gene [36]. Our
results could not confirm this hypothesis because of the
limited extent of the study that did not allow us such a
specific computational analysis.
Genotype/phenotype correlation
Generally, the ADPKD phenotype is very variable and
the correlation between genotype and phenotype is
usually not apparent, even within one family. One of the
explanations could be a different genetic background
and the effect of heritable modifying factors.
The influence of gender, mutation type and mutation
location on phenotype of ADPKD is limited and not
completely clear. A slight correlation between gender
and median age at ESRD onset has been described in
literature (56.1 years for men versus 59.5 years for
women) [6]. Although the influence of gender has been
demonstrated in case of the PKD2 gene too, the most
recent report has not proved this dependency [4,6]. Our
data also suggested a slightly higher mean age of ESRD in
ADPKD females than in males (53.8 ± 12.3 years versus
50.3 ± 11.4 years). The ages of ESRD in Czech patients
compared with those described by Cornec-Le Gall et al.
were slightly lower, but in concordance with observations
made by Torra et al. (49.6 years for men versus 53.1 years
for women) [47].
Another dependency examined within our study was
the effect of distinctive type of mutation on the phenotype
of ADPKD. We observed that the mean age of ESRD is
slightly higher in case of Czech ADPKD patients with
missense mutations and in-frame amino acids deletions
(54.6 ± 14.4 years) in comparison with patients carrying
protein truncating mutations (50.9 ± 11.1 years). This ob-
servation corresponds with a strong correlation between
the mutation type and median age at ESRD onset that has
been recently presented in literature (55.6 years in case of
truncating mutations versus 67.9 years in case of muta-
tions with no truncating effect) [6]. For further examin-
ation of this dependency a bigger data set would be
necessary as only information from 11 patients with
missense mutations and in-frame amino acids deletions
was available.
Two PKD1 mutations were confirmed in a 24-year-old
patient with normal renal function (patient 275 with twomutations within exon 23). The ultrasound of his par-
ents was normal, without cysts. It seems probable that
both mutations were de novo however DNA samples
from parents were not available. Moreover, a family with
large PKD1 deletion was described. The age of ESRD in
two males (40 years and 53 years) was known in this
family. Intrafamiliar variability has been repeatedly
described in PKD families, and was noted in this family,
as well. The clinical course in the male with ESRD at the
age of 40 years was influenced by arterial hypertension.
There were three more affected members in this family
(35–50 years) with normal renal function or only mild
renal insufficiency. The large PKD1 deletion does not lead
to severe clinical course.
The more severe manifestation of the disease in
patients with mutations in the 5′ region of the PKD1
gene has been described in comparison with patients
carrying mutations in the 3′ region [11]. Nevertheless, a
recent study with 741 patients has not shown the signi-
ficant difference between the 5′ and 3′ end regions [6]. In
the case of the PKD2 gene, no clear relationship between
mutation location and ADPKD severity has been found,
either [48]. Within our study, no effect of location of
PKD1 mutations on the mean age of ESRD of Czech
ADPKD patients has been observed.
Detection techniques
Mutation analysis of highly polymorphic PKD genes is
challenging because of the length of genes (especially
PKD1 gene), multi-exon structures, high GC content,
marked allelic heterogeneity and existence of highly
homologous pseudogenes of the PKD1 gene. On average,
as much as 10.1 different sequence changes per patient
are reported in case of the PKD1 gene [12,14]. Few
complete screens of both genes have been already pub-
lished with the use of different molecular techniques,
but all described methods have still a lot of limitations,
including time-demand, high price or insufficient sen-
sitivity. The detection level of the present study is 71%
(40 patients/families with likely pathogenic mutations in
PKD genes from 56 patients in total) which is in accord-
ance with the 75% efficiency reported by Bataille et al.,
where the same method of high resolution melting
(HRM) was used [23]. The cases with no probable muta-
tion found may correspond to allele dropout, different
category of sequence changes that have not been ana-
lyzed within this study (such as deep intronic variants or
missed mutations in promoter regions) or can be caused
by incorrect original diagnosis. Hypomorphic variants or
polygenic inheritance may also play an important role
[15,17]. By denaturing high-performance liquid chro-
matography (DHPLC), approximately 64% efficiency for
definitely pathogenic mutations has been achieved [11]. A
current publication concerning DHPLC presented the
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DHPLC with direct sequencing has increased the level of
detection up to 89% [12]. Similarly, 86% efficiency has
been reported with Transgenomic’s SURVEYOR Nuclease
and WAVE Nucleic Acid High Sensitivity Fragment
Analysis System [28]. Using direct sequencing alone,
different results have been achieved ranging from 64.5% of
mutations detected by Hoefele et al., 78% of probable
pathogenic mutations detected by Garcia-Gonzales et al.
to the highest efficiency of 93.8% reported by Cornec-Le
Gall et al. [6,36,49,50]. In the most recent studies, the new
high-throughput next generation sequencing (NGS) tech-
niques have been tested for mutational analysis of PKD
genes with the maximal detection rate of 63% and 69.4%
[24,25]. The NGS deep sequencing helps with identi-
fication of missed or atypical sequence variants, which
are hardly detectable through the conventional Sanger
sequencing (especially allele dropout, gene conversion
or deep intronic variants). Promising is also the new
LR-PCR Sequencing Method developed by Tan et al. with
very high sensitivity, improved intronic coverage and
marked saving of time and costs [51].
In comparison with other detection techniques, HRM
analysis has good and comparable efficacy. Ninety-six or
even 394 samples could be analyzed at once through the
simple strategy of PCR followed automatically by HRM
analysis. The most important benefits of this method are
thus the savings of time and costs and general conveni-
ence of the working strategy, decreasing the probability
of mistakes within the whole process.
Conclusion
The methods for mutational identification are constantly
improving and enable us to screen even such a complex
gene as PKD1. The HRM and MLPA are relatively fast
and convenient methods that together reached the
detection level of 71%. The question is how to interpret
the data from genetic analysis. The differences in sever-
ity of the disease within affected relatives suggest that
the phenotype of ADPKD is influenced not only by the
type or location of the mutation but also by genetic
background and environmental factors. The assessment
of patient’s prognosis on the basis of molecular diagnostics
is therefore still impossible, but allows us a screening
of presymptomatic relatives and kidney donors. Full
characterization of molecular etiology of ADPKD should
facilitate possible therapeutic intervention.
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